

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nielsen et al

Confirmation No: 1622

Serial No.: 10/582,277

Group Art Unit: To be assigned

Filed: June 9, 2006

Examiner: To be assigned

For: A Cell with Improved Secretion Mediated by MrgA Protein or Homologue

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This application was filed on June 10, 2006 as a national phase application of PCT/DK2004/000859. As indicated in the Transmittal Letter to the DO/EQ/US and the Application Data Sheet, this application claims priority or the benefit of U.S. provisional application no. 60/529,141 filed on December 12, 2003. One of the named is Allan Kent Nielsen who resides in Soborg, Denmark.

The filing receipt received by Applicants contains the following errors:

1. In the domestic priority data, the U.S. provisional application is omitted.
2. The country of residence for Allan Kent Nielsen is misidentified as Germany.

Applicants therefore request the issuance of a corrected filing receipt with complete domestic priority data and the correct country of residence for Allan Kent Nielsen.

Applicants submit that the error was the fault of the USPTO and therefore no fee is due.

Respectfully submitted,

Date: May 7, 2008

/Elias Lambiris, Reg. # 33728/  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097